Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Ischemic-type biliary lesions (ITBLs) are a major cause of graft loss and mortality after orthotopic liver transplantation (OLT). For now, there are still lacking effective treatment for ITBLs. The purpose of this study is to confirm whether human umbilical cord mesenchymal stem cells are effective in the treatment,or prevention of Ischemic-type Biliary Lesions after liver transplantation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yang Yang

Criteria

Inclusion Criteria:

• benign end-stage liver disease patients with liver transplantation.

• ages of 18 and 60 years.

• first liver transplant.

• gamma-glutamyltransferase > 300 U/L for 2 weeks, and there was no or low enhancement of the wall of the hilar bile duct in arterial phase via contrast-enhanced ultrasonography.

• Written informed consent.

Exclusion Criteria:

• second or combined organ transplant recipient.

• vital organs failure (Cardiac, Renal or Respiratory, et al).

• clinically active bacterial, fungal, viral or parasitic infection.

• other candidates who are judged to be not applicable to this study by investigators.